肺血管扩张剂治疗与艾森曼格综合征患者生存改善相关
该研究随访澳大利亚和新西兰12个成人先天性心脏病中心的253例艾森曼格综合征成人患者,中位随访9.1年。72%患者接受至少一种肺血管扩张剂治疗,暴露组死亡/移植风险为4.8%/年,未暴露组为8.4%/年。多变量分析显示肺血管扩张剂暴露与更高生存独立相关(生存HR 2.27,95%CI 1.49-3.45;p<0.001)。
要点
- 肺血管扩张剂治疗与艾森曼格综合征患者更高生存独立相关
- 治疗组基线功能状态更差,但仍显示生存获益
- 就诊时WHO功能分级≥3与更差预后相关
核心结论
- 肺血管扩张剂治疗与艾森曼格综合征患者更高生存独立相关,即使治疗前患者相对更重。
研究设计与样本
- 前瞻性与回顾性随访研究,纳入2004年1月起澳大利亚和新西兰12个成人先天性心脏病中心的253例艾森曼格综合征成人患者。
主要发现
- 患者以女性为主(60%),年龄31(SD 12)岁,诊断时64%为WHO功能分级≥3。
- 中位随访9.1年,72%患者接受至少一种肺血管扩张剂,49%为单药,最常用波生坦(66%,168例),平均治疗时间6(SD 3.6)年。
- 治疗组死亡/移植风险为4.8%/年,未暴露组为8.4%/年。
- 多变量分析显示肺血管扩张剂暴露与更高生存独立相关(生存HR 2.27,95%CI 1.49-3.45;p<0.001)。
- 就诊时WHO功能分级≥3与更差预后相关(死亡HR 1.82,95%CI 1.19-2.78;p=0.006)。
临床怎么用
- 在艾森曼格综合征成人患者中,可考虑肺血管扩张剂治疗以改善生存,即使患者功能状态较差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Eisenmenger syndrome (ES) is a severe form of pulmonary hypertension in adults with congenital heart disease (CHD) and has a poor prognosis. We aimed to understand factors associated with survival in ES and particularly to assess the potential benefits of advanced pulmonary vasodilator therapy (AT). METHODS: From January 2004, when AT became generally available for patients with ES, we followed 253 ES adults from 12 adult congenital heart disease centres across Australia and New Zealand. Demographic, medical and outcome data were collected and analysed prospectively and retrospectively. RESULTS: The patients with ES were predominantly female (60%), aged 31 (SD 12) years. At diagnosis of ES, 64% were WHO functional class ≥3. The most common underlying lesion was ventricular septal defect (33%) with 21% having 'complex' anatomy. Over a median follow-up time of 9.1 years, the majority (72%) had been prescribed at least one AT (49% single agent), mostly bosentan (66%, 168 patients). The mean time on AT was 6 (SD 3.6) years. Those on AT were more functionally impaired at presentation (69% WHO ≥3 vs 51%, p=0.007) and more likely to have been prescribed anticoagulation (47% vs 27%, p=0.003). The risk of death/transplant was 4.8 %/year in AT exposed versus 8.4% in those never exposed. On multivariable analysis, exposure to AT was independently associated with greater survival (survival HR 2.27, 95% CI 1.49 to 3.45; p<0.001). WHO ≥3 at presentation was associated with a worse prognosis (mortality HR 1.82, 95% CI 1.19 to 2.78; p=0.006). CONCLUSION: Treatment with AT was independently associated with greater survival in patients with ES, even though they were comparatively sicker prior to treatment.
引用
- Arnott C, Strange G, Bullock A, et al. Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome. Heart. 2017. PMID: 28794135. doi:10.1136/heartjnl-2017-311876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。